The Potential Protective Role of Resveratrol in Doxorubicin-Induced Cardiac and Hepatic Toxicity in Male Adults Albino Rats.

Hafez, Rabab Nabil; Abdel Rahman, Asmaa; El-Halafawy, Ghada; Abdelghffar, Eman Ali; Abdel-Ghaffar, WAFAA Hassan

doi:10.21608/ajfm.2025.364109.1160

The Potential Protective Role of Resveratrol in Doxorubicin-Induced Cardiac and Hepatic Toxicity in Male Adults Albino Rats.

Document Type : Original Article

Authors

¹ Forensic Medicine & Clinical Toxicology Department, Faculty of Medicine, Ain Shams University

² Forensic and Clinical Toxicology Department. Faculty of Medicine, Ain Shams University

³ Zoology Department, Faculty of Science, Ain Shams University.

⁴ Zoology Department, faculty of Science, Ain Shams University

10.21608/ajfm.2025.364109.1160

Abstract

Introduction: Doxorubicin (Dox) is known to treat Acute myelocytic leukemia and various tumors but is associated with significant cardiac and liver toxicity. Aim: This study evaluated the toxic effects of Dox on these organs pathophysiologically, and the potential protective effects of resveratrol (Rs), which has anti-oxidative and anti-inflammatory properties. Methodology: Fifty male adult albino rats were divided into five groups for treatment, including control, saline, Rs alone, Dox alone (2mg/kg/IP/twice/weekly/for 5 weeks), and Rs pretreatment (20 mg/kg/day/orally/for 6 weeks) followed by Dox (2mg/kg/IP/twice/weekly/for 5 weeks). Results: The results showed severe pathological damage in the heart (including diffuse myomalacia, mild hyalinization, discontinuity of some fibers, loss of the normal striation) and liver (including disrupted architecture, hepatocytes with lytic and coagulative necrosis, fibrosis, Langhans (giant cells invasion) of the Dox group compared with the first three groups. No significant physiological differences were observed among the control, saline, and Rs groups concerning cardiac and hepatic antioxidant levels of TAC/SOD/catalase/MDA/and caspase-3, as well as the cardiac markers (LDH/ CK-MB/AST/and troponin) and hepatic enzymes levels (ALT/AST/and TB). The findings suggest that resveratrol may help mitigate the toxicity of doxorubicin treatment. Conclusions: resveratrol can give hope to improve doxorubicin-related toxicity to a broader extent.

Keywords